Stockscreener 앱 받기
14.60
2.41%
-0.36
전일 마감가:
$14.96
열려 있는:
$14.93
하루 거래량:
1.07M
Relative Volume:
0.79
시가총액:
$737.98M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-3.9566
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
-13.10%
1개월 성능:
-8.18%
6개월 성능:
-7.54%
1년 성능:
+76.97%
1일 변동 폭
$14.45
$15.14
1주일 범위
$14.45
$16.77
52주 변동 폭
$8.19
$19.00
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
200 CROSSING BOULEVARD, FRAMINGHAM, MA
KALV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
14.60 | 756.17M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 재확인 | Needham | Buy |
| 2026-01-06 | 재확인 | Needham | Buy |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Can KalVista Pharmaceuticals Inc withstand a market correction2025 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
Published on: 2026-01-16 10:42:21 - baoquankhu1.vn
Aug Weekly: Can Zoetis Inc sustain its profitabilityOptions Play & Technical Entry and Exit Tips - baoquankhu1.vn
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? - Yahoo Finance
Can KalVista Pharmaceuticals Inc stock sustain revenue growthQuarterly Earnings Report & Long-Term Growth Plans - Bộ Nội Vụ
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 7.2%Time to Sell? - MarketBeat
KalVista reports $49M in 2025 Ekterly revenue, shares rise - MSN
HAE treatment Ekterly hits $49M sales in months since July launch - Angioedema News
The Technical Signals Behind (KALV) That Institutions Follow - Stock Traders Daily
What is HC Wainwright's Forecast for KALV FY2030 Earnings? - MarketBeat
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt? - simplywall.st
Kalvista Stock Surges On Strong EKTERLY Uptake - Nasdaq
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales By Investing.com - Investing.com South Africa
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales - Investing.com Nigeria
Stock Market Today: Dow, Nasdaq 100 And S&P 500 Futures Gain After December Jobs Data— General Motors, Tilray In Focus (UPDATED) - Benzinga
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales By Investing.com - Investing.com South Africa
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales - Investing.com Nigeria
KalVista Pharmaceuticals (KALV) Receives Buy Rating with Increas - GuruFocus
Kalvista stock price target raised to $29 from $28 at Citizens on strong Ekterly launch - Investing.com Australia
KALV: Needham Raises Price Target to $35, Maintains Buy Rating | - GuruFocus
KalVista Stock Pre-Market (+14%) : Reports Strong EKTERLY Launch Revenue - Trefis
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart - MSN
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart - Stocktwits
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY By Investing.com - Investing.com South Africa
KalVista reports $35 million Q4 revenue for oral HAE treatment EKTERLY By Investing.com - Investing.com South Africa
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY - Investing.com Nigeria
KalVista reports $35 million Q4 revenue for oral HAE treatment EKTERLY - Investing.com
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results - The Joplin Globe
Star Tribune - FinancialContent
KalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Will KalVista Pharmaceuticals Inc. (4XC1) stock sustain bullish trend into 2025Weekly Gains Summary & Weekly Breakout Watchlists - Улправда
How KalVista Pharmaceuticals Inc. (4XC1) stock moves in volatile trading sessions - bollywoodhelpline.com
Aug Sectors: Is KalVista Pharmaceuticals Inc stock supported by innovation pipeline2025 Retail Activity & Technical Buy Zone Confirmation - Bộ Nội Vụ
Needham raises Kalvista Pharmaceuticals stock price target on Ekterly launch success - Investing.com Nigeria
KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $32.00 - MarketBeat
KalVista Pharmaceuticals (KALV): Needham Raises Price Target to $32 | KALV Stock News - GuruFocus
Millennium Management LLC Acquires Additional Shares in KalVista Pharmaceuticals - GuruFocus
KalVista Pharmaceuticals Inc 4XC1 Stock Analysis and ForecastTrading Volume Trends & No Fee. No Catch. Just Smart Investment Ideas - Early Times
2025 Drug Launches Underscore Commercial Headwinds For New Products - Citeline News & Insights
Precision Trading with Kalvista Pharmaceuticals Inc. (KALV) Risk Zones - Stock Traders Daily
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 5.1% HigherShould You Buy? - MarketBeat
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):